Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 18.05
AEGR's Cash to Debt is ranked higher than
82% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. AEGR: 18.05 )
AEGR' s 10-Year Cash to Debt Range
Min: 0.02   Max: No Debt
Current: 18.05

Equity to Asset 0.79
AEGR's Equity to Asset is ranked higher than
85% of the 750 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. AEGR: 0.79 )
AEGR' s 10-Year Equity to Asset Range
Min: 0.79   Max: 0.87
Current: 0.79

0.79
0.87
F-Score: 5
Z-Score: 18.05
M-Score: 7.09
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -48.63
AEGR's Operating margin (%) is ranked higher than
51% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.55 vs. AEGR: -48.63 )
AEGR' s 10-Year Operating margin (%) Range
Min: -128.43   Max: -128.43
Current: -48.63

Net-margin (%) -49.82
AEGR's Net-margin (%) is ranked higher than
51% of the 780 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.99 vs. AEGR: -49.82 )
AEGR' s 10-Year Net-margin (%) Range
Min: -130.51   Max: -130.51
Current: -49.82

ROE (%) -48.53
AEGR's ROE (%) is ranked lower than
51% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. AEGR: -48.53 )
AEGR' s 10-Year ROE (%) Range
Min: -103.09   Max: -34.7
Current: -48.53

-103.09
-34.7
ROA (%) -38.42
AEGR's ROA (%) is ranked lower than
52% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. AEGR: -38.42 )
AEGR' s 10-Year ROA (%) Range
Min: -460.23   Max: -6.36
Current: -38.42

-460.23
-6.36
ROC (Joel Greenblatt) (%) -544.36
AEGR's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. AEGR: -544.36 )
AEGR' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -84687.5   Max: -3769.47
Current: -544.36

-84687.5
-3769.47
EBITDA Growth (%) 20.30
AEGR's EBITDA Growth (%) is ranked higher than
84% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. AEGR: 20.30 )
AEGR' s 10-Year EBITDA Growth (%) Range
Min: 0   Max: 20.3
Current: 20.3

0
20.3
EPS Growth (%) 1.70
AEGR's EPS Growth (%) is ranked higher than
72% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. AEGR: 1.70 )
AEGR' s 10-Year EPS Growth (%) Range
Min: 0   Max: 1.7
Current: 1.7

0
1.7
» AEGR's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

AEGR Guru Trades in Q3 2013

Jim Simons 52,800 sh (New)
Andreas Halvorsen 744,788 sh (+1969.2%)
RS Investment Management 396,386 sh (+52.03%)
Steven Cohen Sold Out
» More
Q4 2013

AEGR Guru Trades in Q4 2013

RS Investment Management 534,248 sh (+34.78%)
Andreas Halvorsen 881,333 sh (+18.33%)
Jim Simons Sold Out
» More
Q1 2014

AEGR Guru Trades in Q1 2014

Michael Price 200,000 sh (New)
RS Investment Management Sold Out
Andreas Halvorsen Sold Out
» More
Q2 2014

AEGR Guru Trades in Q2 2014

Jim Simons 76,500 sh (New)
Michael Price 240,000 sh (+20%)
Steven Cohen 923,700 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with AEGR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Michael Price 2014-06-30 Add 20%0.16%$30.35 - $47.11 $ 31.96-14%240000
Michael Price 2014-03-31 New Buy1.1%$43.65 - $73.75 $ 31.96-46%200000
George Soros 2012-06-30 Sold Out 0.01%$11.76 - $16.96 $ 31.96128%0
George Soros 2011-06-30 New Buy0.01%$15.29 - $21.85 $ 31.9681%37500
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Aegerion Pharmaceuticals Inc

Three CEOs Reporting Large Insider Buys
Over the past week we’ve seen several large insider buys as well as several coming from the companies’ CEOs. It is interesting to note when a CEO, or even a CFO, buys because these insiders supposedly have the most intimate knowledge of their company's workings.

Read more...

Ratios

vs
industry
vs
history
P/B 8.83
AEGR's P/B is ranked higher than
54% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. AEGR: 8.83 )
AEGR' s 10-Year P/B Range
Min: 7.12   Max: 24.56
Current: 8.83

7.12
24.56
P/S 9.03
AEGR's P/S is ranked higher than
58% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.72 vs. AEGR: 9.03 )
AEGR' s 10-Year P/S Range
Min: 7.61   Max: 1820.75
Current: 9.03

7.61
1820.75
EV-to-EBIT -16.74
AEGR's EV-to-EBIT is ranked higher than
58% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. AEGR: -16.74 )
AEGR' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -16.74

Current Ratio 5.45
AEGR's Current Ratio is ranked higher than
88% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. AEGR: 5.45 )
AEGR' s 10-Year Current Ratio Range
Min: 0.03   Max: 17.43
Current: 5.45

0.03
17.43
Quick Ratio 5.17
AEGR's Quick Ratio is ranked higher than
89% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. AEGR: 5.17 )
AEGR' s 10-Year Quick Ratio Range
Min: 0.03   Max: 17.43
Current: 5.17

0.03
17.43

Valuation & Return

vs
industry
vs
history
Price/Net Cash 12.29
AEGR's Price/Net Cash is ranked higher than
92% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AEGR: 12.29 )
AEGR' s 10-Year Price/Net Cash Range
Min: 4.01   Max: 23.89
Current: 12.29

4.01
23.89
Price/Net Current Asset Value 10.55
AEGR's Price/Net Current Asset Value is ranked higher than
90% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. AEGR: 10.55 )
AEGR' s 10-Year Price/Net Current Asset Value Range
Min: 4.01   Max: 22.99
Current: 10.55

4.01
22.99
Price/Tangible Book 8.83
AEGR's Price/Tangible Book is ranked higher than
61% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. AEGR: 8.83 )
AEGR' s 10-Year Price/Tangible Book Range
Min: 3.9   Max: 21.65
Current: 8.83

3.9
21.65
Price/Median PS Value 0.21
AEGR's Price/Median PS Value is ranked higher than
99% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.25 vs. AEGR: 0.21 )
AEGR' s 10-Year Price/Median PS Value Range
Min: 0.21   Max: 22.92
Current: 0.21

0.21
22.92
Forward Rate of Return (Yacktman) -14.16
AEGR's Forward Rate of Return (Yacktman) is ranked higher than
56% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. AEGR: -14.16 )
AEGR' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -14.16

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:KYE.Germany
Aegerion Pharmaceuticals, Inc. is a biopharmaceutical company. It develops into commercialization of novel, life-altering therapies for patients with debilitating, often fatal, rare diseases.
» More Articles for AEGR

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 
Weekly CEO Buys Highlight: GEO, TRUE, BANC, AEGR, CLMS Jun 02 2014 
Three CEOs Reporting Large Insider Buys May 22 2014 
Four CEOs Reporting Large Insider Buys May 09 2014 
100 Stocks at All-Time Highs | 60 Dividend Stocks Below the Results Feb 19 2013 
My 3 Favorite Dividend Stocks at All-Time-Highs | Stock List Dec 27 2012 
Weekly CFO Buys Highlight: RXN, XBKS, STAG, AEGR, PZG Apr 02 2012 

More From Our Partners
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Sep 9 2014 - BENZINGA

More From Other Websites
Nasdaq stocks posting largest percentage increases Sep 12 2014
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Sep 09 2014
The Zacks Analyst Blog Highlights: United Therapeutics, Repros Therapeutics, Amgen, Regeneron and... Sep 04 2014
Aegerion Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Conference Sep 03 2014
Aegerion Resolves FDA's Warning on Juxtapid, Lifts Overhang Aug 28 2014
Midday movers: Best Buy, Smith & Wesson & more Aug 27 2014
Aegerion Pharmaceuticals Announces Resolution of Warning Letter for JUXTAPID(R) (lomitapide)... Aug 27 2014
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 21 2014
Biotechnology Stocks to Keep an Eye On Aug 20 2014
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 15 2014
AEGERION PHARMACEUTICALS, INC. Financials Aug 15 2014
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement,... Aug 12 2014
Why Aegerion Pharmaceuticals (AEGR) Stock Is Down Today Aug 12 2014
Aegerion Pharmaceuticals, Inc. Prices $300 Million Convertible Senior Notes Offering Aug 12 2014
Aegerion Pharmaceuticals, Inc. Announces Intention to Offer $250 Million of Convertible Notes Aug 11 2014
AEGERION PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Aug 08 2014
Aegerion Pharmaceuticals Grants Stock Options Under Inducement Program Aug 08 2014
Strength Seen in Aegerion Pharmaceuticals, Inc. (AEGR): Stock Shoots up 16.4% Jul 31 2014
AEGERION PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Jul 30 2014
Aegerion Q2 Loss Narrower than Expected, 2014 View Retained Jul 30 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK